Biovitrum AB

Biovitrum AB (STO:BVT) STOCKHOLM, Sweden and MADISON, New Jersey, USA - November 12, 2008. Biovitrum AB (publ) (STO:BVT) and Wyeth (NYSE:WYE) today announced an extension of the ReFacto® supply agreement until December 31, 2015. Biovitrum will continue to be the sole producer of drug substance for Wyeth for ReFacto®, as well as Xyntha®/ReFacto® AF, the successor products, and will continue to receive royalties from Wyeth's global sales. Biovitrum's co-promotion rights in the Nordic region remain unchanged.

Biovitrum AB (STO:BVT) Strong financial third quarter. Product acquisition from Amgen paves the way to expanded market platform

Biovitrum AB (STO:BVT) Biovitrum would like to invite you to a press and analyst meeting in Stockholm on Wednesday, October 22, in conjunction with the disclosure of the Interim Report January - September 2008. The report will be presented by Biovitrum's CEO Martin Nicklasson and CFO Göran Arvidson. The presentation will be held in English and webcasted.

Biovitrum AB (STO:BVT) In accordance with Biovitrum stock option program 2006:2 TO3 2006/2008, 250 502 new shares have been issued at the price SEK 59.00 per share, resulting in Biovitrum being provided funds of a total of SEK 14 779 618.00. No stock options remain in the stock option program 2006:2 TO3 2006/2008.

Biovitrum AB (STO:BVT) Stockholm September 16, 2008 - Biovitrum AB (publ) (STO:BVT) reported today the start of a clinical phase II study with Exinalda(TM), a candidate drug for the treatment of fat malabsorption. The aim of the study is to document the clinical effect of Exinalda in patients with pancreatic insufficiency as the result of cystic fibrosis. The study comprises 18 patients and is being conducted in Poland and the Netherlands. The results of the study are expected during the first half of 2009.

Biovitrum AB (STO:BVT) STOCKHOLM, Sweden and THOUSAND OAKS, California, USA - September 15, 2008. Biovitrum AB (publ) (STO:BVT) and Amgen (NASDAQ:AMGN) announced today that they have entered into an agreement under which Biovitrum will acquire the marketed biologic therapeutic products Kepivance® (palifermin) and Stemgen® (ancestim) from Amgen, and will also obtain from Amgen a worldwide exclusive license to Kineret® (anakinra) for its current approved indication. The agreement includes an inventory of the three products at an undisclosed value.

Biovitrum AB A busy half-year with focus on specialist care pharmaceuticals and restructuring of R&D

Biovitrum AB COPENHAGEN, Denmark and STOCKHOLM, Sweden- July 16, 2008. Symphogen A/S and Biovitrum AB (publ) (STO:BVT) today announced the recruitment of the first patient into a Phase II clinical trial, initiated in June, to evaluate the safety and efficacy, and explore the dose range of Sym001 in Idiopathic Thrombocytopenic Purpura (ITP) patients. Sym001 is a recombinant, polyclonal anti-Rhesus D antibody product candidate. Symphogen and Biovitrum are jointly developing Sym001 under a 50/50 co-development and commercialization agreement announced in February 2006.